These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15257957)

  • 1. Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.
    Breccia M; De Cuia MR; D'Elia GM; Francesca B; Mandelli F; Alimena G
    Haematologica; 2004 Jul; 89(7):ECR20. PubMed ID: 15257957
    [No Abstract]   [Full Text] [Related]  

  • 2. [Imatinib].
    Urabe A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
    Tefferi A; Kantarjian H
    Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
    Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T
    Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459
    [No Abstract]   [Full Text] [Related]  

  • 6. Atypical chronic myeloid leukaemia with CD117-positive blast cells treated with imatinib: A report of two cases.
    Breccia M; Russo E; De Propris MS; Frustaci A; Alimena G
    Acta Haematol; 2006; 116(3):211-2. PubMed ID: 17016042
    [No Abstract]   [Full Text] [Related]  

  • 7. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
    Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antituberculosis therapy and imatinib for chronic myeloid leukemia.
    Sorà F; De Matteis S; Di Mario A; Maiuro G; Laurenti L; Chiusolo P; Ardito F; Leone G; Sica S
    Clin Infect Dis; 2006 Nov; 43(9):1224. PubMed ID: 17029152
    [No Abstract]   [Full Text] [Related]  

  • 11. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 12. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 13. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
    Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
    Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
    Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V; Vakalopoulou S; Tziomalos K
    Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Imatinib. An anticancer agents indicated in the treatment of chronic myeloid leukemia]].
    Taéron C
    Rev Infirm; 2004 Feb; (98):39-40. PubMed ID: 15042992
    [No Abstract]   [Full Text] [Related]  

  • 19. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
    Champlin RE; Kantarjian H
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):398-400. PubMed ID: 16258420
    [No Abstract]   [Full Text] [Related]  

  • 20. [Imatinib--a new perspective in the treatment of tumors].
    Klener P; Klamová H
    Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.